Filing Flows › CareDx (CDNA) › Q3 2025
CareDx (CDNA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
CareDx (CDNA) reported revenue of $100M for the third quarter 2025 (Q3 2025), +21% from a year earlier and +15% from the quarter before. Operating margin was -0.2%, net earnings $1.7M (1.7% of revenue).
CareDx, Q3 2025: revenue $100M (+21% year over year), operating margin -0.2%, net earnings $1.7M, operating cash flow $37.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $100M | +15% | +21% |
| Operating profit | −$246K | — | — |
| Net earnings | $1.7M | — | — |
| Operating cash flow | $37.4M | +278% | +198% |
| Free cash flow | $36.1M | +306% | +233% |
What changed
Revenue was $100.1M in Q3 2025, up 21% year over year and up 15% from the previous quarter. Testing services revenue was the largest line at 72% of revenue. Testing services revenue added $11.4M year over year (up 19%), 66% of the total change.
Operating costs exceeded revenue by $246K, an operating margin of -0.2%. Total costs grew 4% against revenue growth of 21%. The fastest-growing cost line was Sales & marketing (+23%). Net earnings were $1.7M. The effective tax rate was -0.9%. Non-operating items added $1.9M, 115% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $37.4M (up 198% year over year), 2230% of net earnings. Non-cash charges added back $3.8M of depreciation and amortization and $8.4M of share-based compensation. Working capital and other items added $23.5M. Capital expenditures of $1.3M left free cash flow of $36.1M.
Questions
What was CareDx's revenue in the third quarter 2025?
CareDx (CDNA) reported revenue of $100M for the third quarter 2025 (Q3 2025), +21% from a year earlier and +15% from the quarter before.
Was CareDx profitable in the third quarter 2025?
Operating loss was $246K (-0.2% of revenue) and net earnings $1.7M.
Source: CareDx 10-Q on SEC EDGAR.